Jeffrey J. Sutherland

2.1k total citations
44 papers, 1.5k citations indexed

About

Jeffrey J. Sutherland is a scholar working on Molecular Biology, Computational Theory and Mathematics and Pharmacology. According to data from OpenAlex, Jeffrey J. Sutherland has authored 44 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 19 papers in Computational Theory and Mathematics and 5 papers in Pharmacology. Recurrent topics in Jeffrey J. Sutherland's work include Computational Drug Discovery Methods (19 papers), Bioinformatics and Genomic Networks (5 papers) and Receptor Mechanisms and Signaling (5 papers). Jeffrey J. Sutherland is often cited by papers focused on Computational Drug Discovery Methods (19 papers), Bioinformatics and Genomic Networks (5 papers) and Receptor Mechanisms and Signaling (5 papers). Jeffrey J. Sutherland collaborates with scholars based in United States, Canada and Netherlands. Jeffrey J. Sutherland's co-authors include Donald F. Weaver, Lee A. O’Brien, Michal Vieth, D. H. Robertson, James Stevens, Robert M. Campbell, Jon A. Erickson, David Lillicrap, Keith M. Goldstein and Timothy P. Ryan and has published in prestigious journals such as Journal of the American Chemical Society, Nature Communications and Blood.

In The Last Decade

Jeffrey J. Sutherland

43 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey J. Sutherland United States	23	698	683	165	135	131	44	1.5k
Florian Nigsch Switzerland	21	725 1.0×	582 0.9×	152 0.9×	51 0.4×	130 1.0×	36	1.4k
Nikolaus Stiefl Switzerland	20	742 1.1×	779 1.1×	198 1.2×	73 0.5×	114 0.9×	43	1.5k
Pierre Acklin Switzerland	19	844 1.2×	963 1.4×	263 1.6×	169 1.3×	222 1.7×	28	1.6k
Gennadiy Poda United States	16	808 1.2×	665 1.0×	360 2.2×	68 0.5×	282 2.2×	25	1.7k
Д. А. Михайлов Russia	17	888 1.3×	817 1.2×	192 1.2×	35 0.3×	59 0.5×	49	1.5k
Linli Li China	26	1.2k 1.8×	550 0.8×	444 2.7×	65 0.5×	66 0.5×	111	2.0k
Teruki Honma Japan	31	1.8k 2.6×	701 1.0×	724 4.4×	95 0.7×	121 0.9×	124	3.5k
Mahendra Awale Switzerland	23	761 1.1×	792 1.2×	304 1.8×	29 0.2×	141 1.1×	39	1.5k
Heng Luo China	27	1.1k 1.6×	771 1.1×	231 1.4×	33 0.2×	39 0.3×	90	2.3k
Xiaojun Yao Macao	23	989 1.4×	303 0.4×	211 1.3×	25 0.2×	52 0.4×	99	1.9k

Countries citing papers authored by Jeffrey J. Sutherland

Since Specialization

Citations

This map shows the geographic impact of Jeffrey J. Sutherland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey J. Sutherland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey J. Sutherland more than expected).

Fields of papers citing papers by Jeffrey J. Sutherland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey J. Sutherland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey J. Sutherland. The network helps show where Jeffrey J. Sutherland may publish in the future.

Co-authorship network of co-authors of Jeffrey J. Sutherland

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey J. Sutherland. A scholar is included among the top collaborators of Jeffrey J. Sutherland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey J. Sutherland. Jeffrey J. Sutherland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kunnen, Steven J., Jeffrey J. Sutherland, Panuwat Trairatphisan, et al.. (2025). Utilizing rat kidney gene co-expression networks to enhance safety assessment biomarker identification and human translation. iScience. 28(7). 112978–112978.

Sutherland, Jeffrey J., et al.. (2023). A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs. Nature Communications. 14(1). 4323–4323. 17 indexed citations

Lo, Frederick Yip-Kwai, Jeffrey J. Sutherland, Guray Kuzu, et al.. (2022). “3D, human renal proximal tubule (RPTEC-TERT1) organoids ‘tubuloids’ for translatable evaluation of nephrotoxins in high-throughput”. PLoS ONE. 17(11). e0277937–e0277937. 3 indexed citations

Kunnen, Steven J., Panuwat Trairatphisan, Solène Grosdidier, et al.. (2021). The human hepatocyte TXG-MAPr: gene co-expression network modules to support mechanism-based risk assessment. Archives of Toxicology. 95(12). 3745–3775. 15 indexed citations

Ietswaart, Robert, Seda Arat, Saman Farahmand, et al.. (2020). Machine learning guided association of adverse drug reactions with in vitro target-based pharmacology. EBioMedicine. 57. 102837–102837. 53 indexed citations

Han, Jin H., Alex Chen, Eduard E. Vasilevskis, et al.. (2019). Supratherapeutic Psychotropic Drug Levels in the Emergency Department and Their Association with Delirium Duration: A Preliminary Study. Journal of the American Geriatrics Society. 67(11). 2387–2392. 3 indexed citations

Copple, Ian M., Wouter den Hollander, James L. Maggs, et al.. (2018). Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury. Archives of Toxicology. 93(2). 385–399. 22 indexed citations

Sutherland, Jeffrey J., Ryan D. Morrison, J. Scott Daniels, Stephen Milne, & Timothy P. Ryan. (2017). Managing Psychotropic Medications in Complex, Real-World Patients Using Comprehensive Therapeutic Drug Monitoring. ACS Chemical Neuroscience. 8(8). 1641–1644. 7 indexed citations

Sutherland, Jeffrey J., Thomas M. Daly, Karen Jacobs, et al.. (2017). Medication Exposure in Highly Adherent Psychiatry Patients. ACS Chemical Neuroscience. 9(3). 555–562. 5 indexed citations

10.

Sutherland, Jeffrey J., Yue Webster, Jeffrey A. Willy, et al.. (2017). Toxicogenomic module associations with pathogenesis: a network-based approach to understanding drug toxicity. The Pharmacogenomics Journal. 18(3). 377–390. 64 indexed citations

11.

Ryan, Timothy P., Ryan D. Morrison, Jeffrey J. Sutherland, et al.. (2017). Medication adherence, medical record accuracy, and medication exposure in real-world patients using comprehensive medication monitoring. PLoS ONE. 12(9). e0185471–e0185471. 25 indexed citations

12.

Sutherland, Jeffrey J., Robert A. Jolly, Keith M. Goldstein, & James Stevens. (2016). Assessing Concordance of Drug-Induced Transcriptional Response in Rodent Liver and Cultured Hepatocytes. PLoS Computational Biology. 12(3). e1004847–e1004847. 37 indexed citations

13.

Sutherland, Jeffrey J., Cen Gao, Suntara Cahya, & Michal Vieth. (2013). What general conclusions can we draw from kinase profiling data sets?. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1834(7). 1425–1433. 22 indexed citations

14.

Sutherland, Jeffrey J., Jonathan Low, Wayne Blosser, et al.. (2011). A Robust High-Content Imaging Approach for Probing the Mechanism of Action and Phenotypic Outcomes of Cell-Cycle Modulators. Molecular Cancer Therapeutics. 10(2). 242–254. 26 indexed citations

15.

Low, Jonathan, Louis F. Stancato, Jonathan Lee, & Jeffrey J. Sutherland. (2008). Prioritizing hits from phenotypic high-content screens.. PubMed. 11(3). 338–45. 19 indexed citations

16.

Vieth, Michal, Jeffrey J. Sutherland, D. H. Robertson, & Robert M. Campbell. (2005). Kinomics: characterizing the therapeutically validated kinase space. Drug Discovery Today. 10(12). 839–846. 133 indexed citations

17.

Sutherland, Jeffrey J. & Donald F. Weaver. (2004). Three-dimensional quantitative structure-activity and structure-selectivity relationships of dihydrofolate reductase inhibitors. Journal of Computer-Aided Molecular Design. 18(5). 309–331. 32 indexed citations

18.

O’Brien, Lee A., Jeffrey J. Sutherland, Carol Hegadorn, et al.. (2004). A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers. Journal of Thrombosis and Haemostasis. 2(7). 1135–1142. 15 indexed citations

19.

Sutherland, Jeffrey J., Lee A. O’Brien, David Lillicrap, & Donald F. Weaver. (2004). Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations. Journal of Molecular Modeling. 10(4). 259–270. 56 indexed citations

20.

O’Brien, Lee A., Paula D. James, Maha Othman, et al.. (2003). Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood. 102(2). 549–557. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact